The annual Healey Center International Prize for Innovation in ALS is a global prize celebrating excellence in research for a team of investigators who catalyse exceptional discoveries leading to a transformative advance in therapy development in ALS.
- New legislation would increase oversight of laboratory-developed tests.
- Until now, the potential impact on health care costs of this legislation was unknown.
- The economic effects will depend on how the law is interpreted, a new study shows.
Jochen Lennerz, MD, PhD
It’s very important to align the language in this new law with the intent of what it’s trying to accomplish.
Center for Integrated Diagnostics, Massachusetts General Hospital
BOSTON – Legislation currently under consideration in U.S. Congress would increase regulatory oversight of certain diagnostic tests, and a new study by researchers at Massachusetts General Hospital (MGH) and colleagues from several other institutions demonstrates that its potential impact will depend on key details in the bill’s final language. This study, published in JCO Oncology Practice, offers the first evidence-based analysis of how new rules proposed for the regulation of laboratory-developed tests (LDTs) could affect health care costs in the United States.
“The idea of having more oversight of LDTs is justified,” says Jochen Lennerz, MD, PhD, medical director of the MGH Center for Integrated Diagnostics (CID) and the study’s senior author. “But our results show that it’s very important to align the language in this new law with the intent of what it’s trying to accomplish.”
From a regulatory standpoint, there are two categories of in vitro clinical tests (IVCTs), which include diagnostic tests performed in a test tube, culture dish, or elsewhere outside a living organism. Manufactured tests for many different conditions are commercially available. The Food and Drug Administration (FDA) closely regulates these tests, requiring manufacturers to submit data for premarket approval before they can be sold. However, clinical laboratories at hospitals and in other health care settings can create their own IVCTs for use in-house, which are known as LDTs. Currently, the FDA does not require premarket approval of LDTs and exercises little oversight of their use.
LDTs serve a variety of purposes, but one critically important role is identifying patients for novel drug therapies that target specific DNA variations, particularly if a commercial test is not yet available. This form of therapy, known as personalized medicine, is becoming increasingly important in cancer treatment.
Unfortunately, faulty IVCTs can produce inaccurate results, causing some patients to forgo potentially beneficial treatments and others to receive unnecessary and potentially harmful therapies. The proposed legislation, currently known as the Verifying Accurate and Leading-edge IVCT Development (VALID) Act, clarifies the authority of the FDA over all diagnostics tests.
If passed, VALID would focus on so-called high-complexity IVCTs, which have the greatest potential for patient harm if the results are incorrect. To comply with VALID, clinical laboratories would have to demonstrate accuracy of their LDTs, which includes a process called technology certification.
Lennerz believes that the stringency of how VALID is interpreted, which is not currently defined in the bill, will influence whether the proposed law can improve the quality of LDTs without significantly increasing future health care costs. He joined lead author Richard Huang, MD, and several colleagues in an effort to model the overall expense of maintaining the technology certification framework under VALID for cancer diagnostics. They based their estimates on 2019 data from CID, which performs more than 10,000 high-complexity LDTs for MGH patients each year.
The study found that maintenance costs for a lab performing that volume of LDTs would be $638,000 a year under low stringency and slightly higher ($685,000) under moderate stringency, but soar to $1.2 million under highly stringent enforcement. Extrapolating that data to reflect the added expense for the nation’s 886 cancer treatment centers, complying with VALID would increase U.S. health care costs by $565 million, $606 million, or $1.1 billion over a three-year period, depending on stringency of enforcement.
Lennerz believes the study’s important contribution is putting a price tag on VALID, which no one has yet done. “The key finding is that maintaining this new infrastructure will come at a cost,” he says.
And while those numbers may seem high to some, they should be kept in perspective, says study co-author Jeff Allen, president and CEO of Friends of Cancer Research, a nonprofit patient advocacy organization in Washington, D.C.: “In the United States, we consistently see increases in health expenditures in the realm of $200 billion annually.” Even with added FDA enforcement, the increased costs of VALID amounts to less than 0.5% of annual increased expenditures, he notes. “At the gain of assured quality in testing, the avoidance of medical errors, and improved support for medical decisions, the costs offset. But most important, patient care will improve,” says Allen. VALID has bipartisan support in both houses of Congress, which will likely begin debate on the bill in early summer.
Huang is a former clinical informatics fellow in the Department of Pathology at MGH. Lennerz is also an associate professor of Pathology at Harvard Medical School.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2020, Mass General was named #6 in the U.S. News & World Report list of "America’s Best Hospitals."
About Friends of Cancer Research
Friends of Cancer Research (Friends) is working to accelerate policy change, support groundbreaking science, and deliver new therapies to patients. We unite scientists, pharmaceutical companies, and policy makers with shared trust and guide them toward meaningful cooperation. This collaboration among partners from every healthcare sector ultimately drives advances in science, policy, and regulation that speed life-saving treatments to patients. For more information, please visit https://friendsofcancerresearch.org/.
- Press Release
- May | 14 | 2021
B cells create antibodies, and most produce antibodies in response to a pathogen or a vaccine. A small subset of B cells instead make antibodies that perform vital housekeeping functions. Understanding how epigenetics spur these differences is an important question in immunology.
- Press Release
- May | 12 | 2021
During the development and progression of Alzheimer’s disease, a protein called tau accumulates and spreads in the brain. Understanding the mechanisms behind tau spread—and its consequences—may point to new prevention and treatment strategies for Alzheimer’s disease and other forms of dementia.
- Press Release
- May | 11 | 2021
Regulatory T cells in the brain can be reprogrammed from guarding glioblastoma tumors to attacking them from within.
- Press Release
- May | 10 | 2021
For the first time, researchers have shown how a key reproductive hormone suppresses follicle development and prevents ovulation in females.
- Press Release
- May | 10 | 2021
New research points to a promising strategy to boost tumors’ intake of cancer drugs, thereby increasing the effectiveness of chemotherapy treatments.